Combined genetics and MRD define 3 subsets of adult patients with KMT2A-r BCP-ALL with distinct outcomes. CIR (A) and OS (B) in patients according to oncogenetics and MRD. Patients with Onco⁺ were defined as having at least 1 alteration in TP53 and/or IKZF1, Onco^– as having no alteration in both genes. MRD is based on gKMT2A measured at the end of induction (MRD1).